Eptifibatide

Eptifibatide

CAT N°: 21578
Price:

From 71.00 60.35

Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation.{38053,38054} Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation.{38055} It inhibits ADP-induced citrated blood aggregation (IC50 = 0.11-0.22 ?g/ml) in vitro and in vivo (IC50 = 52 ?g/ml in porcine plasma).{38053,38056} Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.{38057}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-?-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1?6)-disulfide
  • Correlated keywords
    • 148031-34-9 157630-07-4 544430-77-5 eftifibatide integrelin integrilin intrifiban GPIIb IIIa GPIIIa GP-IIb 2b 3a
  • Product Overview:
    Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation.{38053,38054} Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation.{38055} It inhibits ADP-induced citrated blood aggregation (IC50 = 0.11-0.22 ?g/ml) in vitro and in vivo (IC50 = 52 ?g/ml in porcine plasma).{38053,38056} Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.{38057}

We also advise you